US equities |
NVDA $233.97 ▲+1.34% MU $1,072.89 ▼-2.23% SPCX $159.58 ▲+7.77% TSLA $373.28 ▲+5.41% SNDK $1,717.19 ▼-3.94% STX $847.92 ▼-10.33% AMD $634.11 ▲+2.98% INTC $119.98 ▼-0.01%
FinancialContent

Articles published by AstraZeneca

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Perioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin granted Priority Review in the US for patients with muscle-invasive bladder cancer
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 14.3 months as 1st-line therapy in patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
TAGRISSO® (osimertinib) demonstrated unprecedented eight-year landmark survival in early-stage EGFR-mutated lung cancer in ADAURA Phase III trial
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
IMFINZI® (durvalumab) plus tarlatamab demonstrated a statistically significant and highly clinically meaningful improvement in overall survival and progression-free survival in 1st-line extensive-stage small cell lung cancer
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
Tozorakimab demonstrated statistically significant and highly clinically meaningful reduction in COPD exacerbations in OBERON and TITANIA Phase III trials
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
ETCAMAH® (camizestrant) in combination with a CDK4/6 inhibitor approved in the US for 1st-line advanced HR-positive breast cancer
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
AstraZeneca completes global license agreement for oral EGFR inhibitor ZEGFROVY® (sunvozertinib) for lung cancer
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
TEZSPIRE demonstrates positive Phase III results in eosinophilic esophagitis across both co-primary and all key secondary endpoints
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated statistically significant and clinically meaningful improvement in PFS as 1st-line treatment of patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
TAGRISSO® (osimertinib) plus savolitinib demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
Sonesitatug vedotin demonstrated a statistically significant and highly clinically meaningful improvement in overall survival in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
AstraZeneca results: H1 and Q2 2026
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
AstraZeneca and YMCA of the USA Announce Landmark Partnership Aimed to Address Gaps in Cancer Care
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
TRUQAP® (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
Camizestrant Combination Delayed Time to First Progression by 55% and to Second Progression by 37% in Patients With Advanced HR-positive Breast Cancer With an Emergent ESR1 Tumor Mutation in SERENA-6 Trial
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) combined with lenvatinib and TACE reduced the risk of disease progression or death by 30% in embolization-eligible unresectable liver cancer in EMERALD-3 Phase III trial
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
DATROWAY® (datopotamab deruxtecan-dlnk) approved in the US as first TROP2-directed antibody drug conjugate for 1st-line treatment of patients with metastatic triple-negative breast cancer who are not PD-1/PD-L1 inhibitor candidates
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
AstraZeneca to showcase Phase III data in liver, breast and bladder cancers and potential first-in-class rare disease therapy at ASCO 2026
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
BAXFENDY approved in the US as the first and only aldosterone synthase inhibitor treatment for adults with hypertension
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US for two new indications for patients with HER2-positive early breast cancer
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
Perioperative IMFINZI® (durvalumab) plus neoadjuvant EV showed statistically significant and clinically meaningful improvements in event-free survival and overall survival in muscle-invasive bladder cancer in the Phase III VOLGA trial
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
TRUQAP® (capivasertib) recommended by FDA Advisory Committee for PTEN-deficient metastatic hormone-sensitive prostate cancer
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
AstraZeneca results: Q1 2026
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
BREZTRI approved in the US for asthma as first and only triple therapy for patients 12 years of age and older
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
SAPHNELO approved in the US for subcutaneous self-administration as a new autoinjector for the treatment of systemic lupus erythematosus
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
Tozorakimab met primary endpoint in Phase III MIRANDA trial in patients with COPD
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
IMFINZI® (durvalumab) + IMJUDO® (tremelimumab-actl) improves PFS in early liver cancer
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
Tozorakimab met primary endpoint in both OBERON and TITANIA Phase III trials in patients with COPD
From AstraZeneca
Via Business Wire
Tickers AZN
News headline image
AstraZeneca and Joshua Jackson partner to encourage fans to Get Body Checked Against Cancer
From AstraZeneca
Via Business Wire
Tickers AZN
< Previous 1 2 3 4 5 6 7 8 9 10 Next >